Article
Pharmacology & Pharmacy
Paul A. Frohna, Anoshie Ratnayake, Nick Doerr, Asjad Basheer, Laith Q. Al-Mawsawi, Woo Jae Kim, Juan C. Zapata, Xiaorong Wu, Thomas A. Waldmann, Nazli Azimi, Yutaka Tagaya
JOURNAL OF CLINICAL PHARMACOLOGY
(2020)
Article
Gastroenterology & Hepatology
Cezary Ciszewski, Valentina Discepolo, Alain Pacis, Nick Doerr, Olivier Tastet, Toufic Mayassi, Mariantonia Maglio, Asjad Basheer, Laith Q. Al-Mawsawi, Peter H. R. Green, Renata Auricchio, Riccardo Troncone, Thomas A. Waldmann, Nazli Azimi, Yutaka Tagaya, Luis B. Barreiro, Bana Jabri
Review
Immunology
Thomas A. Waldmann, Milos D. Miljkovic, Kevin C. Conlon
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Review
Immunology
Thomas A. Waldmann, Sigrid Dubois, Milos D. Miljkovic, Kevin C. Conlon
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Oncology
Anusara Daenthanasanmak, Yuquan Lin, Meili Zhang, Bonita R. Bryant, Michael N. Petrus, Richard N. Bamford, Craig J. Thomas, Milos D. Miljkovic, Kevin C. Conlon, Thomas A. Waldmann
Summary: Adult T-cell leukemia (ATL) is an aggressive malignancy caused by HTLV-1, with potential therapeutic benefits in targeting the JAK/STAT and PI3K/AKT/mTOR pathways. Combination treatment of Upadacitinib with mTOR inhibitors shows promising anti-proliferative effects in ATL cell lines and in reducing tumor growth in mice, providing a new direction for ATL treatment.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Yunlong He, Nagesh Pasupala, Huijun Zhi, Batsuhk Dorjbal, Imran Hussain, Hsiu-Ming Shih, Sharmistha Bhattacharyya, Roopa Biswas, Milos Miljkovic, Oliver John Semmes, Thomas A. Waldmann, Andrew L. Snow, Chou-Zen Giam
Summary: Constitutive NF-kappa B activation induces senescence through R-loop accumulation and DNA double-strand breaks, while ATL cells exhibit deficiencies in TC-NER endonucleases and accumulate R-loops. These vulnerabilities may serve as potential targets for ATL treatment.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Immunology
Javier Traba, Michael N. Sack, Thomas A. Waldmann, Olga M. Anton
Summary: This article discusses the main effects of the tumor microenvironment (TME) on the metabolism and function of immune cells, and reviews emerging strategies to boost immune cell metabolism for promoting anti-tumor effects, either as monotherapies or in combination with conventional chemotherapy for optimizing cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Sigrid P. Dubois, Milos D. Miljkovic, Thomas A. Fleisher, Stefania Pittaluga, Jennifer Hsu-Albert, Bonita R. Bryant, Michael N. Petrus, Liyanage P. Perera, Jurgen R. Muller, Joanna H. Shih, Thomas A. Waldmann, Kevin C. Conlon
Summary: The study demonstrated that administering IL-15 as CIV-5 significantly expanded NK cells with increased cytotoxic functions. There were no dose-limiting toxicities in the CIV-5 regimen, and a substantial increase in CD8(+) T cells was observed.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Marcia Bellon, Izabela Bialuk, Veronica Galli, Xue-Tao Bai, Lourdes Farre, Achilea Bittencourt, Ambroise Marcais, Michael N. Petrus, Lee Ratner, Thomas A. Waldmann, Vahid Asnafi, Antoine Gessain, Masao Matsuoka, Genoveffa Franchini, Olivier Hermine, Toshiki Watanabe, Christophe Nicot
Summary: The epigenetic alteration of FHIT was found to be specifically present in chronic and acute ATL patients, while absent in asymptomatic HTLV-I carriers and TSP/HAM patients. The extent of FHIT methylation in ATL patients was quantitatively comparable in virus-infected and non-infected cells. Results suggest that germinal epigenetic mutation of FHIT may predispose individuals to the development of ATL diseases.
Article
Oncology
Hongbo Wang, Wei Wei, Jing-Ping Zhang, Zhihui Song, Yangyang Li, Wenming Xiao, Yijun Liu, Mu-Sheng Zeng, Michael N. Petrus, Craig J. Thomas, Marshall E. Kadin, Masao Nakagawa, Thomas A. Waldmann, Yibin Yang
Summary: Aberrant activation of NF-kappa B is a key oncogenic mechanism in B-cell lymphoma, while its role in anaplastic large cell lymphomas (ALCL) remains unclear. Study on ALCL cell line models revealed supporting roles of NFKB2 and NIK pathway, with STAT3 identified as the major mediator for NIK-dependent NF-kappa B activation in ALCL. The findings suggest potential benefits of combined NIK and JAK inhibitor therapy for NIK-positive ALK- ALCL with JAK/STAT3 somatic mutations.
Meeting Abstract
Hematology
Milos D. Miljkovic, Kevin C. Conlon, Jennifer Albert, Deborah Allen, Thomas A. Waldmann
Article
Multidisciplinary Sciences
Zhihui Song, Wei Wei, Wenming Xiao, Essel D. Al-Saleem, Reza Nejati, Liqi Chen, Jiejing Yin, Joseph Fabrizio, Michael N. Petrus, Thomas A. Waldmann, Yibin Yang
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2020)
Article
Cell Biology
Sigrid Dubois, Thomas A. Waldmann, Jurgen R. Muller
CELLULAR IMMUNOLOGY
(2020)